MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Gastroenterology_Gastrointestinal (to include Liver, Pancreas & metabolic dysfunction-associated steatotic liver disease (MASLD), Gout, MASH (Metabolic dysfunction-associated steatohepatitis), formerly, NASH (Non-Alcoholic SteatoHepatitis)Non-Alcoholic SteatoHepatitis (NASH)
Rampart Bioscience, Inc.
Organization & Developments:Rampart Bioscience
Parents
Rampart Bioscience, Inc.
Children
*Rampart’s proprietary HALO platform is designed to produce highly potent, durable, and redosable therapies.
*The company is initially focused on genetic diseases affecting the liver and its first program is designed to treat hypophosphatasia, a rare genetic disease
*The company’s lead program is for the treatment of hypophosphatasia (HPP), a rare, often fatal genetic disease that prevents bone mineralization.
2023: Rampart Bioscience Announces $85M Series A Financing to Develop Novel DNA-Based Medicines with Veteran Team
2026: Rampart Closes Down Less Than 2 Years After Launch
Jumps
Finance & Acquisitions: Rampart Bioscience
Key People: Rampart Bioscience